Specific keynote: immunological therapy for ovarian cancer

Risk-Stratified versus Cytology-Based Triage of Non-HPV 16/18-Positive for Detection of High-Grade Cervical Intraepithelial Neoplasia: Protocol of a Non- Inferiority Randomized Controlled Trial.

Research square·2026

Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Uterine serous carcinoma and germline genetic testing: patterns of referral, completion and pathogenic variant detection.

Journal of medical genetics·2026

Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes.

Cancers·2025

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.

Immunotherapy·2025

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Gynecologic oncology·2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Gynecologic oncology·2026

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Gynecologic oncology·2026

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Gynecologic oncology·2026

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Gynecologic oncology·2026

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Gynecologic oncology·2026

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms.

The Journal of dermatology·2026

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.

Apoptosis : an international journal on programmed cell death·2026

Intersession reliability of transcranial magnetic stimulation measures of interhemispheric inhibition.

Neuroscience·2026

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Frontiers in oncology·2026

Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

Nature reviews. Cancer·2026

Circulating levels of TL1A and its decoy receptor DcR3 in systemic sclerosis.

Clinical rheumatology·2026

Related Experiment Videos

Specific keynote: immunological therapy for ovarian cancer

Related Concept Videos

Risk-Stratified versus Cytology-Based Triage of Non-HPV 16/18-Positive for Detection of High-Grade Cervical Intraepithelial Neoplasia: Protocol of a Non- Inferiority Randomized Controlled Trial.

Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors.

Uterine serous carcinoma and germline genetic testing: patterns of referral, completion and pathogenic variant detection.

Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes.

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms.

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.

Intersession reliability of transcranial magnetic stimulation measures of interhemispheric inhibition.

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

Circulating levels of TL1A and its decoy receptor DcR3 in systemic sclerosis.

Related Experiment Videos

Specific keynote: immunological therapy for ovarian cancer

Related Concept Videos

Related Articles